UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 13, 2011
Biogen Idec Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
|
Delaware
(State or other jurisdiction
of incorporation)
|
|
0-19311
(Commission
file number)
|
|
33-0112644
(IRS Employer
Identification No.) |
| |
|
|
|
133 Boston Post Road, Weston, Massachusetts
(Address of principal executive offices)
|
|
02493
(Zip Code) |
Registrant’s telephone number, including area code: (781) 464-2000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
Biogen Idec Inc. has amended its Supplemental Savings Plan and Voluntary Board of Directors Savings
Plan, effective as of January 1, 2012, to permit voluntary deferrals into these plans of equity
based awards granted under Biogen Idec’s 2008 Omnibus Equity Plan and 2006 Non-Employee Directors
Equity Plan, respectively, and any successor plans.